1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
5.41%
Cash & equivalents yoy growth near the Drug Manufacturers - Specialty & Generic median of 5.41%. Seth Klarman would see it as in line with peers. Evaluate why the company holds additional cash.
-22.53%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-1.52%
Near the Drug Manufacturers - Specialty & Generic median of -1.52% for total liquid asset growth. Charlie Munger would check if this is standard for the industry cycle.
-8.31%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of -4.03%. Jim Chanos might see a serious red flag in ballooning receivables.
-0.98%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of -0.57%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-6.86%
Other current assets growth less than half of Drug Manufacturers - Specialty & Generic median of 1.96%. Joel Greenblatt would see a leaner short-term structure vs. peers.
-2.98%
Below half the Drug Manufacturers - Specialty & Generic median of 1.97%. Jim Chanos would question if the company faces working capital strain.
-97.03%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -3.12%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-35.03%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-2.24%
Near the Drug Manufacturers - Specialty & Generic median of -2.24%. Charlie Munger would see standard intangible growth relative to sector norms.
-25.12%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of -2.23%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
35.32%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
1363.28%
Below half of Drug Manufacturers - Specialty & Generic median of -4.80%. Joel Greenblatt sees fewer expansions of "other" long-term items vs. peers.
-22.03%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -11.55%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-18.81%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -0.12%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-0.16%
Payables growth below half of Drug Manufacturers - Specialty & Generic median of 0.69%. Joel Greenblatt sees more conservative payables management vs. peers.
-29.61%
Similar to Drug Manufacturers - Specialty & Generic median of -29.61%. Charlie Munger sees typical short-term debt levels in the industry. Check coverage ratios.
5.51%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
No Data
No Data available this quarter, please select a different quarter.
701.98%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 44.84%. Jim Chanos suspects a potential short-term burden spike.
-5.87%
Below half Drug Manufacturers - Specialty & Generic median of 10.40%. Joel Greenblatt sees more conservative short-term leverage than peers.
-6.68%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -3.49%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-1.62%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
361423.53%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 4.62%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-4.52%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -2.61%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-5.03%
Below half Drug Manufacturers - Specialty & Generic median of 1.80%. Joel Greenblatt sees a much lower liability expansion vs. peers.
6.45%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-28.35%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.47%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
13355.71%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-21.40%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -9.01%. Joel Greenblatt sees stronger equity growth vs. peers.
-18.81%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.12%. Joel Greenblatt sees more aggressive expansions than peers.
-16.40%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-7.99%
Near Drug Manufacturers - Specialty & Generic median of -7.99%. Charlie Munger sees typical overall debt changes in the sector.
-21.80%
Near Drug Manufacturers - Specialty & Generic median -21.80%. Charlie Munger sees typical yoy changes in net debt among the sector.
